Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in Treatment of Moderate-to-Severe Primary RLS
NCT01668667 is registered in ClinicalTrials.gov with XenoPort, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in Treatment of Moderate-to-Severe Primary RLS
- Lead sponsor
- XenoPort, Inc.
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- June 30, 2012
- Completion date
- November 30, 2013
- Enrollment
- 501 (actual)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.